Bioprocessing Summit Europe Highlights Innovations in Gene Therapy CMC and Manufacturing – Yahoo Finance

Spark Therapeutics, Ultragenyx and Others to Headline March 24-26 Meeting in Barcelona

With the global market for gene therapy expected to hit $13 billion (USD) by 2024 (Research And Markets), Bioprocessing Summit Europe is returning March 24-26, 2020 with its popular Gene Therapy CMC and Manufacturing track.

Expanding to a new venue to accommodate increased registrations, the meeting will take place at The Crowne Plaza Barcelona (Spain)Fira Center.

From the Plenary Keynote by Diane Blumenthal, PhD, Head, Technical Development, Spark Therapeutics, the first company to obtain approval of a gene-therapy product in the EU and US, to insights from Biogen, Sanofi, Vivet Therapeutics, Takeda and Ultragenyx, content will focus on accelerating therapies into the market.

"There is a real thirst for knowledge about how to rapidly deploy biologics while ensuring quality and cost-efficiency. This conference reveals the critical challenges facing the manufacture, analysis and control of these exciting new therapies," said Dan Barry, Senior Conference Director, CHI.

Among highlights:

The event will also include:

See bioprocessingeurope.com.

About Cambridge Healthtech InstituteCambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Pharma Week, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT World, Clinical Research News and Diagnostics World.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200211006146/en/

Contacts

Dawn Ringel+1-781-449-8456, dawn@ringelpr.com

See the original post:

Bioprocessing Summit Europe Highlights Innovations in Gene Therapy CMC and Manufacturing - Yahoo Finance

University of Minnesota Medical School Ranks 27th in 2019 NIH Rankings – Yahoo Finance

The U of M increases three spots in Blue Ridge Institute of Medical Research rankings

Minneapolis, MN, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The Blue Ridge Institute for Medical Research recognizes the University of Minnesota Medical School as the 27th most funded institution by the National Institutes of Health (NIH) in the 2019 NIH rankings.

The University of Minnesota Medical School is ranked 27th nationally in this years rankings, improving from last years spot as 30th (and 33rd in 2017). In addition, five of the Medical Schools departments Biochemistry, Molecular Biology and Biophysics; Neuroscience; Family Medicine and Community Health; Pediatrics; and Rehabilitation Medicine ranked in the top 10 for department-specific rankings. Several other departments also improved rankings in 2019.

The continued progress of our medical school's climb in the NIH rankings reflects the incredible work taking place every day on our campus and in our healthcare facilities by our faculty, researchers and students, said University of Minnesota President Joan T.A. Gabel. We look forward to building on this sustained success as we seek to solve the most pressing healthcare issues here in Minnesota and around the world."

The NIH is the largest federal provider of basic research money to universities. Each year, the Blue Ridge Institute evaluates NIH data tables and ranks universities based on their annual NIH grant support. Improving the Medical School rankings is a top priority of the Board of Regents as a measure for advancing the University.

Rankings are good indicators of how we are building momentum at the Medical School, said Jakub Tolar, MD, PhD, Dean of the University of Minnesota Medical School and Vice President for Clinical Affairs. They help us recruit and retain our faculty, physicians, staff, and learners, generate community support, and most importantly build trust with our patients. We are grateful for the support of President Gabel and our Board of Regents, as well as the strong partnership we have with the State of Minnesota in advancing our mission.

About the University of Minnesota Medical School

The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. Visit med.umn.edu to learn how the University of Minnesota is innovating all aspects of medicine.

Naomi McDonaldUniversity of Minnesota Medical School6123019525naomim@umn.edu

Link:

University of Minnesota Medical School Ranks 27th in 2019 NIH Rankings - Yahoo Finance

Study Shows That Caris Life Sciences’ ADAPT Biotargeting System Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer…

First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery

IRVING, Texas, Feb. 12, 2020 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research,illustrating that use of the Company's proprietary ADAPT Biotargeting System can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate (LNCaP).

Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

The paper, "ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes," also demonstrates that the ADAPT platform can be a powerful method that allows for the enrichment of polyligands that can distinguish even between different subpopulations of the same disease.

The results show that the ADAPT Biotargeting System has the resolution and sensitivity to discover differences in protein complexes using exosomes secreted by cancer cells from the same tumor type.

"The results of this research are highly significant in that they show that the ADAPT system can be deployed against multiple cancer types in various biological matrices and offers broad potential applications in biomarker discovery," said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences, and an author of the study. "Further, we were able to show that in prostate cancer, ADAPT not only discriminated between cancer types but between subtypes of a specific lineage. We anticipate that this could potentially help inform treatment decisions based on the patient's specific molecular profile in prostate cancer and across a range of tumor types."

"The differences in the composition of the Endosomal Sorting Complex Required For Transport (ESCRT) pathway and associated complexes between exosomes derived from VCaP and LNCaP cells could point to them as novel biomarkers for these different prostate cancers," said Michael Famulok, Ph.D., University of Bonn (Germany), Life & Medical Sciences Institute (LIMES), Max Planck Fellow and co-author of the study. "We look forward to further investigating this potential and how the ADAPT system can be used to gain a greater understanding of the molecular composition of cells across tumor types."

The ADAPT Biotargeting System is Caris' proprietary unbiased profiling platform that uses a broad library of synthetically-manufactured molecules (aptamers) that bind to a wide range of biological targets and characterize complex biological systems in their native state, enabling them to profile biological samples at a systems-wide scale.

Thepaperwaspublishedonline on January 28 inNucleic Acids Research,andisavailableonlinehere and DOI:https://doi.org/10.1093/nar/gkaa034.

About Caris Life Sciences

Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions.

Story continues

Caris is also advancing precision medicine with Next Generation Profiling that combines its innovative service offerings, Caris Molecular Intelligence and ADAPT Biotargeting System, with its proprietary artificial intelligence analytics engine, DEAN, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Whole transcriptome sequencing with MI Transcriptome provides the most comprehensive and unique RNA analysis available on the market and covers all 22,000 genes, with an average of 60 million reads per patient, to deliver extremely broad coverage and high resolution into the dynamic nature of the transcriptome. Assessing the whole transcriptome allows us to dig deeper into the RNA universe to uncover and detect fusions, splice variants, and expression changes that provide oncologists with more insight and actionable information when determining treatment plans for patients.

Caris Pharmatech, a pioneer of the original Just-In-Time research system with the largest research-ready oncology network is changing the paradigm from the traditional physician outreach model to a real-time approach where patient identification is completed at the lab and the physician is informed so that the patient can be enrolled days earlier, and remain in the local physician's care, without having to travel to a large central trial site. This fundamentally redefines how pharmaceutical and biotechnology companies identify and rapidly enroll patients in precision oncology trials by combining Caris' highest quality industry leading large-scale molecular profiling services with Pharmatech's on-demand site activation and patient enrollment system.

Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visitwww.CarisLifeSciences.comor follow us on Twitter (@CarisLS).

Media Contact:Lindsey BailysGCI Healthlindsey.bailys@gcihealth.com +1-212-798-9884

View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-that-caris-life-sciences-adapt-biotargeting-system-has-discovered-protein-expression-pattern-differences-between-two-prostate-cancer-patient-subpopulations-301002804.html

SOURCE Caris Life Sciences

More here:

Study Shows That Caris Life Sciences' ADAPT Biotargeting System Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer...

It’s all in the delivery nanoparticle platform could transform medical treatments – Princeton University

Optimeos Life Sciences, a startup founded by two Princeton University faculty members, has reached agreements with six pharmaceutical companies to develop therapeutics using a Princeton-developed drug delivery technology. The collaborations have the potential to improve the effectiveness of medications for the treatment of diseases, ranging from cancer to diabetes.

Optimeos, founded in 2016 by Robert Prudhomme, professor of chemical and biological engineering, and Shahram Hejazi, a faculty memberinthe Keller Center for Innovation in Engineering Educationandelectrical engineering,focuses on bringing technology developed over 15 years in Prudhommes lab to market. The technology, called flash nanoprecipitation, enables the encapsulation of drugs into nanoscale particles that improve delivery and effectiveness.

The startupOptimeos,founded by two Princeton faculty members, has agreements with pharmaceutical companies to bring a nanoscale drug delivery system to market. Developed in Robert Prudhommes lab, the system is a vehicle for delivering medications to precise locations in the body or the interior of cells to treat myriad diseases, including cancer and diabetes. Shown is an artists rendering of Optimeos nanoparticle system.

Illustration by Rachel Davidowitz

The new venture extends the impact of the technology, which already is being used in a project with the Bill and Melinda Gates Foundation. The foundation awarded Prud'homme'slab a $1.2 million grant in 2016 to apply their technology to increase the effectiveness of drugs used in global health. Solutions for global health problems have to be low cost and robust, and the flash nanoprecipitation process is both. The method has been applied to three drugs sponsored by the Gates Foundation. The first was for a drug to treat diarrhea in infants caused by drinking polluted water, the second a tuberculosis drug, and the third a single-dose treatment for malaria.

Optimeos new agreements involve creating improved delivery methods for six different medicines. The names of the six biopharmaceutical companies are currently undisclosed due to the proprietary nature of the ventures. The targeted indications for the various projects are immuno-oncology, autoimmune diseases, diabetes, diseases of the central nervous system and ocular diseases.

These new projects address an inverse set of constraints to that of the Gates Foundation. With Gates, the goal is to take drugs that normally dissolve poorly in the body, because they are water-resistant, and use the delivery system to increase absorption. These projects also need the formulations to be inexpensive, as well as impervious to high humidity and other extreme storage conditions. In contrast, the drug companies working with Optimeos need methods for delivering highly soluble biologics a class of therapeutics including proteins, peptides and nucleic acids.The structural complexity of biologics imparts higher potency and greater specificity, which causes fewer side effects. However, biologics require delivery through frequent injections, and their activity is restricted to targets outside the walls of individual cells, unless sophisticated pharmaceutical formulations are used.

The future of therapeutics are potent biological drugs, many of which have delivery challenges with respect to how much drug needs to be delivered to exactly where in the body, while minimizing side effects, Hejazi said.

Optimeos is overcoming the limitations of biologics by encapsulating them into carefully designed nanoparticles that are 10-times smaller than a red blood cell, or into larger microparticles about the width of a human hair. Such particles have been difficult to manufacture in a reproducible and scalable way, until now.

To make these particles, Optimeos first creates primary nanoparticles in which the drug-filled core is covered by a skin of specially designed polymers. These primary nanoparticles can then be coated with additional polymers that are engineered to interact with specific tissues or cells in the body. These coated nanoparticles could deliver drugs to more precise locations in the body or into the interior of cells. Alternatively, the primary nanoparticles can be assembled into larger composites, much like a cluster of grapes. These microparticles slowly release the encapsulated therapeutic, over a period of weeks to months.

One use of these slow-releasing particles is in the treatment and management of diabetes. In 2019, Optimeos received funding through a National Science Foundation grant to develop a once-monthly injection of liraglutide, a non-insulin medicine used to treat type II diabetes and obesity. Liraglutide is currently administered by a daily injection. The Optimeos formulation aims to reduce the total amount of drug needed, reduce side effects and reduce the frequency of injections. These attributes enhance patient comfort, adherence to treatment regimens, quality of life, cost of care, as well as the medical outcomes, said Robert Pagels, director of R&D for the company and former graduate student of Prudhomme.(As a student in 2017, Pagels' pitch of the technology won first place at the Keller Center's annual Innovation Forum.)

What makes Optimeos approach novel is that the particles can be easily scaled to accommodate mass production needed for the marketplace. I would say none of the technologies out there that are being published on or worked on can be, in fact, scaled up," said Hejazi.

As the onetime head of the Kodak Molecular Imaging Group, now Carestream, Hejazi knew that a persistent problem in the marketplace is that many innovations in nanotechnology cannot be reproduced consistently at industrial scales. Flash nanoprecipitation and its corollary, called inverse flash nanoprecipitation, solve that problem, Hejazi said.

Most methods of creating nanoparticles require combining active ingredients in precise proportion to each other to create consistently sized nanoparticles. This can often be done effectively in small volumes in the laboratory, but cannot be translated to large-scale production. To solve this challenge, flash nanoprecipitation uses multiple, continuous, high-velocity streams containing the active ingredients that constantly combine at the correct proportions within specially engineered mixing chambers. To create more nanoparticles, the process can be left to run over longer time periods. To increase speed of production, the thickness of the streams can be increased, as long as they are in correct proportion to each other. In effect, it is an assembly line approach to mixing the agents.

Pictured at Princeton Innovation Center BioLabs, team members from left: Shahram Hejazi, Bumjun Kim, Robert Pagels, Robert Prud'homme, Chester Markwalter and Madeleine Armstrong.

I have always been passionate about solving health care problems, said Hejazi. Through his industrial contacts, he identified problems the technology could potentially solve. Once the researchers demonstrated that the technology could meet industry demands, the team filed a patent for inverse flash nanoprecipitation in 2016. This patent, written by Pagels and Prudhomme, details how the flash nanoprecipitation process can be used to encapsulate water-soluble drugs such as biologics. This was a major innovation first developed by Pagels in his doctoral research. He flipped the flash nanoprecipitation process (hence the term inverse) to encapsulate soluble drugs, rather than water-insoluble drugs. This made the technology applicable to biologics, and opened up this fast-growing market as a potential target.

Hejazis experience in industry and venture capital provided the vision that drove the founding of the company. Hejazi helped to raise capital, and the team formed a sponsored research agreement with Princeton to continue developing the technology at Princeton. Optimeos also hired recent graduates from Prudhommes lab to work in the company.

Prudhomme sees Optimeos bringing his scientific goals to fruition. My academic research has focused on understanding the fundamental principles behind polymer assembly and processing to enable us to make elegant nanoparticles, said Prudhomme.However, as an engineer, I also want to do something that can make an impact on human health, as opposed to just trying to do a one-shot thing that is beautiful and advances science.

Optimeos story is part of a wider effort at Princeton to move discoveries from University labs to the market and to benefit society more broadly.

The Office of Technology and Licensing at Princeton educates researchers in the steps needed to commercialize technologies and offers entrepreneurial resources, said Anthony J. Williams, new ventures associate in the office.

In recent years, the technology licensing office at Princeton has doubled the creation of startups growing out of faculty research.

Princeton and other universities have been commercializing research since the 1980s when the Bayh-Dole Act allowed institutions to market research that was funded through federal grants. Since then, some of the biggest entrepreneurial success stories at Princeton have been the drug Alimta, a highly effective drug for certain lung cancers, and a breakthrough that tripled the effectiveness of organic LEDs (OLEDS), a display technology now widely used in flat-screen televisions and smartphones.

Princeton isnt an ivory tower," said Williams. Princeton is developing a lot of innovative technologies and a lot of great inventions that can do good in the world.

View post:

It's all in the delivery nanoparticle platform could transform medical treatments - Princeton University

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference – Yahoo Finance

SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m. EST on February 25, 2020 in New York City.

The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriads website at http://www.myriad.com.

About Myriad GeneticsMyriad Genetics, Inc., is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

See more here:

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference - Yahoo Finance

No. 474: On molecular diagnostics, robo-busts and T Rex and happy birthday to the author of your youth – Innovate Long Island

Back stretch: Welcome to Wednesday, dear readers, and the clubhouse turn of our latest socioeconomic sprint.

Have you seen me: National Lost Penny Day on Lincolns birthday? Makes cents.

Its Feb. 12 out there, replete with offbeat observations: choose from National Lost Penny Day, National Plum Pudding Day and Valentines Hug Day, a cuddly precursor to the big lovers day.

They do: Speaking of lovers, its also a notable date for same-sex unions National Freedom to Marry Day, which was actually started by a law firm but earns a shoutout here.

Georgia on our mind: To our many readers in The Peach State, a joyous Georgia Day, recalling the Feb. 12, 1733, establishment of the then-Colonial province.

Sparta something big: Happy anniversary also to Michigan State University, home of the mighty Spartans, founded on this date in 1855.

Face it: Turning to sports innovations, to the delight of receivers and the chagrin of dentists, the catchers mask was patented by inventor Frederick Thayer on Feb. 12, 1878.

And it was this date in 1879 when North Americas first artificial ice-skating rink opened inside Madison Square Garden.

But whos counting: Thomas Edison racked up nine total patents on Feb. 12 four in 1884, two in 1889 and three in 1895, including his incandescent electric lamp.

Other notable innovators earning patent protections on this date include automotive and electronics icon James Packard, who landed the very first of his 43 patents this covering an Igniting Device for Hydrocarbon Engines on Feb. 12, 1901.

Use it or lose it: Fiji was the first nation to ratify the historic Paris Agreement on climate change.

A change is gonna come: And it was this date in 2016 when Fiji became the first nation to ratify the Paris Agreement, an environmental accord under the United Nations Framework Convention on Climate Change.

One-hundred-ninety-four other countries including the United States, albeit temporarily would follow.

Honestly: Happy birthday, Abe an imperfect man with an unerring sense of justice, a leader during a time of unparalleled crisis and an enduring tribute to the solemn weight and responsibility of the U.S. presidency, Abraham Lincoln would be 211 years old today.

Also born on Feb. 12 were the king of origin stories, English naturalist Charles Darwin (1809-1882); American paleontologist Barnum Brown (1873-1963), who discovered the first Tyrannosaurus Rex fossils and evidence of many other dinosaur species; American physicist and Nobel laureate Julian Schwinger (1918-1994), who helped square quantum mechanics with Einsteins theory of relativity; and Swedish actress Maud Adams (born 1945), still the only performer to play two different Bond girls in the long-running spy series.

Its me, Judy: Blume has beaten back critics with numerous awards and 82 million copies sold.

Full Blume: And take a bow, Judy Blume the beloved (and sometimes controversial) author of honest, timeless and influential adolescent fiction turns 82 today.

Give your first favorite writer, your fathers 1974 fantasy woman and all the other Feb. 12 innovators your best at editor@innovateli.com give us the story tips and calendar items, please and thank you.

About our sponsor:Farrell Fritz, a full-service law firm with 15 practice groups, advises startups on entity formation, founder and shareholder agreements, funding, executive compensation and benefits, licensing and technology transfer, mergers and acquisitions and other strategic transactions.The firms blog,New York Venture Hub, discusses legal and business issues facing entrepreneurs and investors.

BUT FIRST, THIS

Park place: Albanys investments in New Yorks state parks appear to be paying off, with Gov. Andrew Cuomo trumpeting a banner year in 2019 for statewide park attendance including turnout at several recently refurbished Long Island sites.

New Yorks state parks, historic sites, campgrounds and officially sanctioned hiking trails welcomed a record-breaking 77.1 million visitors in 2019, an estimated 4 percent increase (nearly 3 million visitors) from 2018 numbers, according to the governors office, which also counts a roughly 33 percent jump (about 19 million annual visits) since Cuomo took office in 2011.

Cuomo credited efforts like the $90 million NY Parks 2020 plan, which has brought facility upgrades to Bethpage State Park (where annual attendance grew by 18 percent in 2019), Sunken Meadow State Park (annual attendance up 13 percent) and a host of other state properties on and off Long Island. The NY Parks 2020 initiative has revitalized our state parks and historic sites, Cuomo said Tuesday. Tourism is booming in New York and these beautiful sites are drawing visitors to all corners of the state.

Jeff Boyd: Molecule man.

Atta Boyd: A renowned expert in cancer genetics and clinical molecular diagnostics has joined the Northwell Health Cancer Institute.

Boasting three decades-plus of cancer-research experience, Jeff Boyd has been named vice president and chief scientific officer of the Cancer Institute and director of its Center for Genomic Medicine. Boyd, who most recently served as associate deputy director of the Miami Cancer Institute at Baptist Health South Florida, also will become a professor at Cold Spring Harbor Laboratory and member of the CSHL Cancer Center.

His primary function at the Northwell Health Cancer Institute will be heading up a new, state-of-the-art Molecular Diagnostics Laboratory the perfect challenge for the veteran researcher, according to Northwell Health Senior VP and Cancer Institute Director Richard Barakat. Genomics has become an important piece to helping us understand the genetic roots of the various forms of cancer, Barakat said Tuesday. We are extremely fortunate to have an internationally known genomics expert such as Dr. Boyd join the Cancer Institutes leadership team.

TOP OF THE SITE

Made for walking: And thats just what this multifaceted boot camp will do, not only teaching learners to code but putting them on the path to 21st century employment.

Robo cop: If Long Island-based autodialer assassin Nomorobo was any closer to a new federal crackdown on illegal robocalls, it would need a badge.

Growing Hain: Discontinued operations are still a drag, but the bottom line is slowly brightening for Lake Success-based global distributor Hain Celestial.

VOICES

Going to extremes: Students on the educational extremes special-ed students needing the most help, high-achieving aces needing more challenges have it roughest in distant rural districts. Voices columnist and K-12 education ace Harry Aurora wants to bring the solution to them.

STUFF WERE READING

Start your engines: Forbes takes a spin on the future of automotive innovation.

Water works: Engadget dives into rainwater as a renewable energy source.

Weather (or not): Popular Mechanics reviews 150 years of forecasting innovations.

RECENT FUNDINGS

+ Outset Medical, a California-based medtech developing innovative hemodialysis systems, raised $125 million in Series E equity financing led by D1 Capital Partners, with participation from Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisor and funds advised by T. Rowe Price Associates.

+ Accion Systems, a Massachusetts-based in-space propulsion system provider, raised $11 million in Series B funding co-led by Boeing HorizonX Ventures and Shasta Ventures.

+ Sonoma Biotherapeutics, a California- and Washington State-based company developing regulatory T cell therapies for autoimmune and degenerative diseases, raised $40 million in Series A financing. Backers included Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures and 8VC.

+ Houwzer, a Pennsylvania-based real estate brokerage, raised $9.5 million in Series A funding led by Edison Partners, with participation from Admiral Capital Group and real estate investor Ira Lubert, and new investors GO Philly Fund and Chestnut Street Ventures.

+ Lumos Diagnostics, a Florida-based healthcare company providing complete point-of-care diagnostic test solutions, closed a $15 million Series A funding round. Australian commercialization company Planet Innovation made the investment.

+ Suzy, a New York City-based consumer-insight platform, closed a $12 million Series C funding round led by Bertelsmann Digital Media Investments, with participation from Foundry Group and Triangle Peak Partners, and existing investors Tribeca Venture Partners and 35 Ventures.

BELOW THE FOLD

Rocks solid: Behold, the new whiskey rebellion.

Eat: The Mars menu may convince astronauts to stay home.

Drink: What whiskey can teach us about innovation.

Be merry: Does innovation create happiness, or vice versa? You decide.

For tomorrow we fly: With the help of the Regulatory & Government Relations Practice Group and all the other topflight resources waiting at Farrell Fritz, one of the amazing firms that support Innovate LI. Check them out.

See the original post here:

No. 474: On molecular diagnostics, robo-busts and T Rex and happy birthday to the author of your youth - Innovate Long Island

$3.75m awarded to transform the way ovarian cancer is treated – News – The University of Sydney

Cancer Council has awarded its annual $3.75 million Translational Program Grant to a research team led by Professor Anna deFazio from the University of Sydney, exploring how to better personalise ovarian cancer treatment for Australian women.

Professor Anna deFazio and her team will spend the next five years creating a process by which ovarian cancer patients can have their cancer comprehensively analysed to determine its molecular profile. If standard treatments are not effective, patients can be matched with an appropriate clinical trial, based on the individual characteristics of their tumour.

This will improve treatment outcomes by ensuring that treatment approaches offered to an ovarian cancer patient are those with the highest likelihood of being successful for their specific subtype of the disease.

Professor deFazio, who is the Sydney West Chair in Translational Cancer Research and co-director of the Centre for Cancer Research at the Westmead Institute for Medical Research (WIMR), is hopeful that this research will transform the way women with ovarian cancer are treated.

Many people dont know that ovarian cancer has the lowest survival rate of any womens cancer in Australia, said Professor deFazio, from the University of Sydney School of Medicine in the Faculty of Medicine and Health.

Currently, only around 45 percent of ovarian cancer patients will survive for five years. Unlike many other cancers, these survival odds have only slightly improved in the last two decades one of the main reasons for this is that each ovarian cancer differs significantly in its genetic and molecular make-up, which results in widely varied treatment outcomes.

Encouragingly, the last few years have seen a rapid expansion in the number and variety of targeted cancer treatment options."

We will work to provide the missing link in this treatment path, generating the data and processes to match patients with the ideal treatment for their cancer type, said Professor deFazio.

The University of Sydney-led team has assembled an expert team of researchers and clinicians to make this happen, including from WIMR, The Crown Princess Mary Cancer Centre, Westmead Hospital, the Prince of Wales Hospital, Royal Hospital for Women, Royal North Shore Hospital, Royal Prince Alfred Hospital, Chris OBrien Lifehouse, the University of Technology Sydney, the Childrens Medical Research Institute, and from interstate, the Peter MacCallum Cancer Centre, and overseas, from the National Cancer Institute in the United States.

To reach their goal, Professor deFazios team will analyse the molecular profile of more than 300 ovarian cancer patients in NSW to better understand the subsets of ovarian cancer and how each type responds to specific treatments. The team will also look at ways of more simply communicating complex molecular test results to the treating clinical team, so they are easier to interpret.

Finally, Professor deFazios team will use patient samples to print 3D models of ovarian tumours to test treatment approaches and help design new early phase clinical trials.

Professor Karen Canfell, Director of Research at Cancer Council NSW, is proud the organisation was able to fund such innovative research: We only award our Translational Program Grant to cancer research that will rapidly translate research discoveries into clinical practice and policy, she said.

Read the original here:

$3.75m awarded to transform the way ovarian cancer is treated - News - The University of Sydney

Discovery raises Prospect of Universal Cancer Therapy – Labmate Online

The use of T-cell therapies for cancer - where immune cells are removed, modified and returned to the patients blood to seek and destroy cancer cells includes the use of CAR-T treatments which are personalised to each patient; however, this is said to target only a few types of cancers and has not been successful for solid tumours, which make up the vast majority of cancers.

Researchers at Cardiff University have now discovered T-cells equipped with a new type of T-cell receptor (TCR) which identifies and kills most human cancer types.

Conventional T-cells can recognise small parts of cellular proteins bound to cell-surface molecules called human leukocyte antigen (HLA), allowing killer T-cells to see whats occurring inside the cells by scanning their surface. HLA varies widely between individuals which has created barriers to creation of a T-cell-based treatment that can target most cancers in all people.

Now the findings of the Cardiff study(1) describe a unique TCR that can recognise many types of cancer via a single HLA-like molecule called MR1. Unlike HLA, MR1 does not vary in the human population - meaning it is a hugely attractive new target for immunotherapies.

T-cells equipped with the new TCR were shown, in the lab, to kill lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells, while ignoring healthy cells.

Professor Andrew Sewell, lead author of the study and an expert in T-cells from Cardiff Universitys School of Medicine, said: Cancer-targeting via MR1-restricted T-cells is an exciting new frontier - it raises the prospect of a one-size-fits-all cancer treatment; a single type of T-cell that could be capable of destroying many different types of cancers across the population. Previously nobody believed this could be possible.

Experiments are under way to determine the precise molecular mechanism by which the new TCR distinguishes between healthy cells and cancer. The researchers believe it may work by sensing changes in cellular metabolism which causes different metabolic intermediates to be presented at the cancer cell surface by MR1.

The Cardiff group hope to trial this new approach in patients towards the end of this year following further safety testing. Professor Sewell said a vital aspect of this ongoing safety testing was to further ensure killer T-cells modified with the new TCR recognise cancer cells only.

"There are plenty of hurdles to overcome; however if this testing is successful, then I would hope this new treatment could be in use in patients in a few years time, he said.

Further information at http://www.cardiff.ac.uk

Read the rest here:

Discovery raises Prospect of Universal Cancer Therapy - Labmate Online

Scientists Study Sweat, the Small Stuff – UANews

Imagine if you could know the status of any molecule in your body without needing to get your blood drawn. Science fiction? Almost but researchers at the University of Arizona are working on ways to do this by measuring molecules in sweat.

When physicians take blood samples from patients, they send the samples to labs to be analyzed for biomarkers. These biological clues indicate everything from cholesterol levels to disease risks, and they can be used to monitor patient health or make diagnostic decisions. The same biomarkers also are found in sweat.

Using $519,000 in funding from the SEMI Nano-Bio Materials Consortium, or SEMI-NBMC, Erin Ratcliff, a materials science and engineering professor and head of the UArizona Laboratory for Interface Science of Printable Electronic Materials, is leading a project to develop new ways of collecting and analyzing the clues sweat has to offer. Ultimately, this work could allow physicians to use patient sweat samples in the same way they currently use blood samples, for a less invasive and more informative approach to establishing and monitoring patient health.

Whats unique about this is that we are combining biology and engineering expertise to develop a wearable device that will detect molecules in sweat, so you dont have to get your blood drawn to know the health status of your immune system, your nervous system, indeed, any system in the body, said co-investigator and sweat biomarker pioneer Esther Sternberg, M.D. The goal, eventually, is to create a device that will provide physicians and health care providers the ability to monitor your health status continuously and in real-time without needing to draw blood.

We are pleased to sponsor and eager to complete this project with the University of Arizonas impressive team bridging the disciplines of engineering and life sciences, said Melissa Grupen-Shemansky, chief technology officer and executive director of SEMI-NBMC. A concerted interdisciplinary approach at the early stages of R & D is relatively new, and there is much learning on both sides. The University of Arizona team brings unique strengths in both areas, and we are excited to be partnering and collaborating with them.

Ratcliffs co-investigators are J. Ray Runyon, a research assistant professor in the Department of Environmental Science, and Sternberg, research director for the Andrew Weil Center for Integrative Medicine; director of the Institute on Place, Wellbeing, and Performance; and the Andrew Weil Inaugural Chair for Research in Integrative Medicine. All three researchers are members of the BIO5 Institute.

Standardized Sample Collection

In order to study sweat, researchers need to collect samples of it, and there are a number of ways to do so.

The obvious idea would be to make a patch that gets information from many pores at once, but the problem is that this creates a space between the patch and your skin, and you have to wait for it to fill up with sweat, Ratcliff said. We hypothesize that while youre waiting, these molecules the very molecules youre trying to detect and analyze are changing chemically.

The teamsfirst task is to develop new, continuous and hands-free collection devices that deliver high-quality, standardized sweat samples. This will allow health care professionals to gain a more holistic picture of a patient's bodily systems over an extended period, rather than the snapshot a blood draw can provide of a particular moment.

Currently, sweat labs across the world are using different methods to collect samples, which limits researchers ability to compare data. Standardizing the collection method could provide researchers, including medical device developers, with a new degree of confidence in sweat sample data.

High-quality data, with respect to different target molecular biomarkers in sweat, requires that a high-quality sample be collected, Runyon said. This will be the first hands-free method that will truly take into account the interplay of the chemistry of sweat, the target biomarker and the device material.

Low-level Detection

The team is also developing methods for researchers to detect and analyze neuropeptides in the collected samples. Used by neurons to communicate with each other, these small molecules are involved in biological functions, including metabolism, reproduction and memory.

Commercial wearable devices monitor metrics like heart rate, and some use sweat sensors to monitor dehydration level. Measuring neuropeptides, however, will allow researchers to zoom in millions of times closer to investigate stress and relaxation responses at the molecular level.

The idea is that your sweat is reflecting your nervous system all of the neurotransmitters your body uses to signal between the brain and the rest of the body, Ratcliff said. Monitoring this biochemical response continually, over a 24-hour cycle, can inform us about the health of the wearer and also act as a diagnostic tool.

Here is the original post:

Scientists Study Sweat, the Small Stuff - UANews

Nuclear Medicine Imaging Market To Reach USD 5.13 Billion By 2027 | Reports And Data – Yahoo Finance

Nuclear Medicine Imaging Market Size USD 3.36 billion in 2018, CAGR of 4.7%, Nuclear Medicine Imaging Industry Trends Rising occurrences of cancer

New York, Feb. 11, 2020 (GLOBE NEWSWIRE) -- The global nuclear medicine imaging market is expected to reach USD 5.13 Billion by 2027, according to a new report by Reports and Data. The growth of the nuclear medicine imaging market is primarily owing to the increasing prevalence of target diseases.

Cancer has a significant impact on the society in the U.S. and across the globe. It has been estimated that 1,735,350 new cancer cases were diagnosed in the U.S. and 609,640 people suffered death from the disease. The number of new incidences of cancer is 439.2 per 100,000 men and women annually and the number of cancer-related morbidity is 163.5 per 100,000 men and women annually. Moreover, it has been estimated that in 2017, 15,270 children and adolescents in the age range of 0-19 years were diagnosed with cancer out of which 1,790 suffered death owing to the disease. In the year 2017, an estimated USD 147.30 billion was spent on cancer care in the U.S.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2415

There is an increasing demand for detecting subclinical disease that require the development of imaging procedures that can precisely locate diseased tissue whereby it can be treated with a minimally invasive and image-guided method. The molecular imaging, which is a type of medical imaging that offers detailed pictures of happenings inside the body at the molecular and cellular level, is one of the most lucrative areas in the field of imaging technology. Nuclear medicine imaging finds application in the field of molecular targeting, which in turn, is likely to propel the market growth in the future.

Further key findings from the report suggest:

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/nuclear-medicine-imaging-market

For the purpose of this report, Reports and Data have segmented the global nuclear medicine imaging market on the basis of type, application, end-users, and region:

Type Cause Outlook (Revenue, USD Million; 2016-2027)

ApplicationOutlook (Revenue, USD Million; 2016-2027)

End-UsersOutlook (Revenue, USD Million; 2016-2027)

Order Now: https://www.reportsanddata.com/checkout-form/2415

Market segment by Region/Country include:

Browse more similar reports on medical imaging category by Reports And Data

Cardiac Arrhythmias Monitoring Devices Market - https://www.reportsanddata.com/report-detail/cardiac-arrhythmias-monitoring-devices-market

Aesthetic Lasers Market - https://www.reportsanddata.com/report-detail/aesthetic-lasers-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:John WatsonHead of Business DevelopmentReports And Data | Web: http://www.reportsanddata.comDirect Line: +1-212-710-1370E-mail: sales@reportsanddata.com

Read more from the original source:

Nuclear Medicine Imaging Market To Reach USD 5.13 Billion By 2027 | Reports And Data - Yahoo Finance

Malouf Collaborates with American Heart Association to Promote Healthy Living – Furniture Today

This press release is submitted and shown here in its original form, unedited by Furniture Today.

LOGAN, UtahFor National American Heart Month, Malouf has teamed up with the American Heart Association (AHA) for its Life Is Why We Give campaign. These two organizations will work together to increase awareness about the heart-health benefits of sleep as well as raise funds to help fight heart disease and stroke.

At Malouf, we believe a good nights rest is key to living a healthier life, said Scott Carr, brand manager for Malouf. Research tells us that heart disease and stroke are leading causes of death in the U.S. and that sleep deprivation can be a contributing factor. Thats why we want to promote the importance of sleep and how it can lead to better heart health.

From now through April, Malouf will also donate a percentage of sales to the AHA, which will support the organizations ongoing research, training and education efforts.

The American Heart Association is committed to be a relentless force to create a world of longer, healthier lives, said Kim Gourley, business development director for the AHA Utah Division. We couldnt accomplish what we do without the support of millions of volunteers, donors and companies like Malouf and their support of the Life Is Why We Give campaign. The fundraising efforts of Malouf provide the resources needed to make the greatest possible impact on health, both on a community and a global level.

In March, Malouf will attend the AHAs annual Go Red for Women luncheon. Attendees are invited to talk with a representative and test some of the companys innovative sleep products. To learn more about Malouf and the other health benefits of sleep, visit maloufsleep.com/blog.

About Malouf

A leader in the furniture and bedding industry, Malouf offers a wide range of innovative products including mattresses, adjustable bed bases, furniture, pillows, sheets, mattress protectors, bed frames and mattress toppers. Malouf products are available in over 15,000 retail partner locations in the U.S. and its growing international team now serves over 25 countries. Known for its commitment to quality, pricing and service, Malouf continues to expand its vertical integration and technology capabilities to better serve its customers with more than 400 global patents and trademarks. Malouf, a Certified B Corporation, was founded in 2003 by Sam and Kacie Malouf and is headquartered in Logan, Utah. To learn more, visit maloufsleep.com.

About Go Red for Women

The American Heart Associations Go Red for Women movement is the trusted, passionate, relevant force for change to end heart disease and stroke in women all over the world. While nearly 80 percent of cardiac events can be prevented, cardiovascular disease is the leading cause of death in women, claiming the lives of 1 in 3 women. For 15 years, Go Red for Women has provided a platform for women to come together, raise awareness, fund lifesaving research, advocate for change and improve the lives of all women everywhere. The American Heart Associations Go Red for Women movement is nationally sponsored by CVS Health, with additional support from national cause supporters. Connect with us on GoRedforWomen.org, Facebook, Twitter or by calling 1-888-MY-HEART (1- 888-694-3278).

###

Here is the original post:
Malouf Collaborates with American Heart Association to Promote Healthy Living - Furniture Today

Baptist Has Heart: Baptist Health Teaches Importance on hands-on CPR – KFSM 5Newsonline

Please enable Javascript to watch this video

FORT SMITH (KFSM) --

February is heart health month and throughout the month we will be hearing from Baptist Health on ways to promote healthy living for your heart.

Did you know 350,000 people a year go into cardiac arrest outside of the hospital?

In honor of American heart month, Baptist Health is teaching you how to save one of those lives.

90 percent of cardiac arrests that happen in the home die," said Jeremy Ibison. Sebastian County rescue team supervisor Jeremy Ibison says by learning hands-on Cpr you could increase the heart attack survival rate by 3 times.

Theres always been this fear I think on the community of mouth to mouth and responding and doing CPR is difficult its not difficult but its very simple," said Ibison. Joseph Kennon with Baptist Health tells us hands-on CPR takes only a few simple steps

All you need to do is activate EMS, dial 9-1-1 and then get the patient hands in the center of the chest and push hard and fast at the rate of 100 beats per minute," said Kennon.

Experts with Baptist Health are going out in the community to teach this simple skill in hopes of saving a life.

If people will be unafraid to react and help the better our survival rates will be," said Ibision.

Community members will get a chance to receive hands-only CPR training, during a seminar focused on heart health February 19th at Baptist Health Hospital in Fort Smith.

To register for the event, call 1-888-BAPTIST or visit baptist-health.com.

The American Heart Association has a video at cpr.heart.org showing the importance of learning hands-CPR as well as showing a step-by-step on what to do.

Segment Sponsored By:Baptist Health

Read more:
Baptist Has Heart: Baptist Health Teaches Importance on hands-on CPR - KFSM 5Newsonline

National Storage Affiliates Trust (NSA) overbought Stock to Bite? We have reviewed it – News Welcome

The stock now we are analyzing at is National Storage Affiliates Trust (NSA) which is now in overbought queue as the Relative Strength Index has been observed at 73.3. As commonly stock is overbought when RSI goes above 70 (look further in the section of technical indicators).

There are a lot of factors to determine whether trading of National Storage Affiliates Trust (NSA) stock is going to end in profit or not but one of the most commonly known important factors has remained the overbought and oversold conditions. So, identifying oversold and overbought stocks is an important skill for every investor or trader. Commonly, traders use technical indicators for oversold and overbought stocks while investors use fundamental factors. Most common Technical indicator that is used to identify overbought and oversold stocks is the Relative Strength Index or called RSI. While most common fundamental indicator that Investors cognize to identify overbought and oversold stocks is P/E Ratio.

How much NSA Stocks is Volatile?

Now we will look for the boiling points and excitability of NSA stock. Last weeks volatility stood at 1.65% and last months volatility marked at 1.51%. Volatility of a stock indicates how tightly the price of a stock is constellated around the mean or moving average. A Stocks volatility is generally associated with investment risk; however, traders can also use it to lock in superior returns. Volatility is also measured by ATR which is an exponential moving average (14-days) of the True Ranges. The stocks ATR value pointed at 0.55.

At this moment, Stocks beta measure is 0.3. Beta is also one of the most popular indicators to measure risk of stock trading. It is a measure of a stocks volatility in relation to the market. Analysts also use it often when they need to determine risk profile of a stock. If beta is higher than 1 then risk is higher and if beta is lower than 1, then risk will be low.

Now here, we will be looking at the trend of NSA stocks performance for different time intervals in order to evaluate the companys share value step by step.

National Storage Affiliates Trust Stock Performance:

Traders shown interest in National Storage Affiliates Trust (NSA) as it recorded negotiations of 284168 shares while stock maintained an average volume of 356.05K shares. It has a market capitalization of $2.16B. NSA stock recognized return of 4.50% over last weekly trading activity and showed performance of 7.08% over monthly period. Shares are now at 12.81% for the quarter and 13.26% for the last six months. The company is driving a 24.78% of return over the course of past one year and is now with performance of 8.45% so far this year. National Storage Affiliates Trust traded with move of 1.39% at $36.46 per share on Tuesday trading session. Shares of company positioned at 0.83% from its 52-week high price while it has been noted 34.24% away from low price over the last 52-weeks.

National Storage Affiliates Trust Stock Look at Technical Side:

Most commonly used indicator to identify overbought and oversold conditions is Relative Strength Index (RSI). RSI is actually a range bound oscillator which is scaled mainly from 0 to 100. RSI from 30 to 70 are considered as a normal state but a RSI indicates the oversold situation when it comes below 30 and If RSI of a stock goes above 70 then it indicates the overbought situation. So as Currently Relative Strength Index (RSI-14) reading of National Storage Affiliates Trust (NSA) stock is 73.3, technically its an overbought stock.

Though, occasionally stocks can indicate an opposite short-term movement then it becomes important to look for trades in direction of a bigger trend. Like when bigger trend of prices stayed down when RSI was over 70 and bigger trend of stock price stayed up while RSI is below 30 then a 14-day RSI can be considered as a short-term indicator. So, in that situation a Simple Moving Average (SMA) can be crucial to look.

Simple Moving Average calculated as an average of the last N-periods (20-Day, 50-Day, 200-Day). A Simple Moving Average is one of the most flexible as well as most-commonly used technical analysis indicators. It is highly popular among traders, mostly because of its simplicity. It works best in a trending environment. Any type of moving average can be used to generate buy or sell signals and this process is very simple. National Storage Affiliates Trust (NSA) stock price is above from its 20 days moving average with 4.37% and trading above from 50 days moving average with 7.14%. The stock price is performing along above from its 200 days moving average with 13.20%.

NSA Stock Under Profitability Spotlight

Net profit margin of the company is -7.30% that shows how much the company is profiting by every dollar of sales. Operating Margin is noted at 32.10%.

Return on Assets (ROA) shows that how much the company is profitable as compared to its total assets which is -0.90% for stock. On the other hand, Return on Equity (ROE) is -3.80%. ROE actually measures financial performance and could be thought of as the return on net assets. It is considered a measure of how effectively management is using a companys assets to create profits. Return on Investment (ROI) is 5.00%. ROI measures the efficiency of investments. It helps to directly evaluate the amount of return on a specific investment, relative to the total investments cost.

Forward price to earnings ratio of 87.02.

Analysts Estimation:

Now at last but not the least, we will review what the Analysts are buzzing about this Stock. Looking for Analysts opinion is also important to understand where the stock is heading. Analyst has some hope that stock may be reaching the Target Price value of $34.88 in coming one year period. The Target Price expected by analysts that is achievable in short term period (1 year). Analysts Mean Recommendation of the stock is now at 2.3 (1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). EPS growth for the next year is expected to be 59.92% and projected to gain growth of 391.40% for this year. Earnings per share EPS is one of the most important variables in determining a shares intrinsic value. EPS (ttm) is reported at -0.47. Analysts have some long term expectations that stock could hit EPS growth of 11.00% in next 5 years period while EPS growth seen at 34.10% for past 5 years period.

See original here:

National Storage Affiliates Trust (NSA) overbought Stock to Bite? We have reviewed it - News Welcome

Posted in NSA

Nanomedicine Market to Witness Increasing Growth $261063 Million at CAGR of 12.6% In 2023 – PharmiWeb.com

UPDATE AVAILABLE ON-DEMAND

The globalnanomedicine marketwas valued at $111,912 million in 2016, and is projected to reach $261,063 million by 2023, growing at a CAGR of 12.6% from 2017 to 2023. The drug delivery segment accounted for nearly two-fifths share of the global market in 2016.

Nanomedicine is an application of nanotechnology that deals in the prevention & treatment of diseases in humans. This technology uses submicrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as, to reduce renal excretion, improve the ability of drugs to accumulate at pathological sites, and enhance the therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.

Download Free Report Sample @https://www.alliedmarketresearch.com/request-sample/2021

The global market is driven by increase in the development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need of therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, growth of healthcare facilities in emerging economies is anticipated to provide numerous opportunities for the market growth.

The vaccines segment is expected to register a significant CAGR of 13.2% throughout the forecast period. The treatment segment accounted for about fourth-sevenths share in the global market in 2016, accounting for the highest share during the forecast period. This is due to the high demand for therapeutics among patient and rise in the incidence of chronic diseases.

The neurological diseases segment is expected to grow at the highest CAGR of 13.9% during the forecast period, owing to high demand for brain monitoring & treatment devices and drugs. The oncological diseases segment accounted for the highest revenue in 2016, with one-third share of the global market, and is expected to maintain its dominance throughout the forecast period.

Get a purchase Enquiry @https://www.alliedmarketresearch.com/purchase-enquiry/2021

In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the global market, and is expected to continue this trend due to increased adoption of nanomedicines, especially in China, India, and the other developing economies. In addition, rise in investments by key players in the field of nanomedicines is key driving factor of the Asia-Pacific market.

The Major Key Players Are:

Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

The other prominent players Are:

Celgene Corporation, UCB (Union Chimique Belge) S.A., AMAG Pharmaceuticals, Nanospectra Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Leadiant Biosciences, Inc., Epeius Biotechnologies Corporation, Gilead, and Cytimmune Sciences, Inc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information:https://www.alliedmarketresearch.com/library-access

Similar Reports:

India Disposable Gloves Market

ASEAN Blood Pressure Monitoring Devices Market

North America Medical Tourism Market

Companion Diagnostic Market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies clients insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesUSA/Canada (Toll Free):+1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK:+44-845-528-1300Hong Kong:+852-301-84916India (Pune):+91-20-66346060Fax:+1(855)550-5975help@alliedmarketresearch.comWeb:https://www.alliedmarketresearch.comMarket Pulse:https://blog.alliedmarketresearch.comFollow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

Go here to read the rest:
Nanomedicine Market to Witness Increasing Growth $261063 Million at CAGR of 12.6% In 2023 - PharmiWeb.com

Socialism and Atheism Still US Political Liabilities – Gallup

Story Highlights

WASHINGTON, D.C. -- More than nine in 10 Americans say they would vote for a presidential candidate nominated by their party who happened to be black, Catholic, Hispanic, Jewish or a woman. Such willingness drops to eight in 10 for candidates who are evangelical Christians or are gays or lesbians. Between six and seven in 10 would vote for someone who is under 40 years of age, over 70, a Muslim or an atheist.

Just one group tested -- socialists -- receives majority opposition. Less than half of Americans, 45%, say they would vote for a socialist for president, while 53% say they would not.

Willingness to Vote for a Party's "Well-Qualified" Candidate for President, Based on Candidate Characteristics

% Yes, would vote for that person; Selected trend

These findings are based on a Gallup question asking, "Between now and the 2020 political conventions, there will be discussion about the qualifications of presidential candidates -- their education, age, religion, race and so on. If your party nominated a generally well-qualified person for president who happened to be [characteristic], would you vote for that person?"

Gallup first tested Americans' willingness to vote for candidates who don't fit the traditional Protestant white male mold in 1937, asking that year whether they would support a well-qualified Catholic, Jew or woman for president. Support for a woman as president was only 33% at that time but has since grown, as has support for other diverse candidates added to the list over the decades.

Since 1958, the sharpest increase in voting tolerance has been for blacks, followed by atheists, women, Jewish candidates and Catholics. More recently, the biggest shift has been for gay or lesbian candidates.

The latest results are based on a Gallup poll conducted Jan. 16-29, 2020. When Gallup last measured these attitudes, in 2019, the results were within a few percentage points of those found today.

Democrats express at least somewhat more willingness than Republicans to support most of the candidate types tested, with the widest gaps seen for Muslims, atheists and socialists. While at least two in three Democrats say they would vote for presidential candidates with these profiles, support among Republicans drops to just over 40% for Muslims and atheists, and to only 17% for socialists.

Republicans are more accepting than Democrats of evangelical Christians and candidates over 70. While President Donald Trump falls into the latter category, so do four of the leading Democratic candidates: Bernie Sanders, Joe Biden, Elizabeth Warren and Michael Bloomberg.

Republicans and Democrats are about equally likely to support Catholic and Jewish candidates.

Willingness to Vote for Candidates With Diverse Characteristics, by Party ID

% Yes, would vote for that person

The views of political independents fall midway between those of Republicans and Democrats for several candidate types -- including socialists, with less than half of independents saying they would vote for such a person.

Independents are closer to Democrats than Republicans in their greater reluctance to support an evangelical Christian candidate, and in their greater willingness to support a candidate who is a woman, gay or lesbian, someone under age 40, a Muslim or an atheist.

As the 2020 Democratic presidential primaries get underway, it may be instructive to know that little prejudice stands in the way of Democratic as well as national support for candidates who happen to be Catholic, Hispanic, Jewish or female. Being especially young or advanced in age could pose minor appeal problems.

Being gay or lesbian, Muslim, an atheist or a socialist wouldn't cause much stir among Democrats, but these candidates could have difficulty attracting support from Republicans and, to a lesser extent, from political independents.

Learn more about public opinion metrics that matter for the 2020 presidential election at Gallup's 2020 Presidential Election Center.

View complete question responses and trends.

Learn more about how the Gallup Poll Social Series works.

Continued here:

Socialism and Atheism Still US Political Liabilities - Gallup

Atheist Gives U. of Texas $1 Million Endowment to Study Non-Religious Americans – Friendly Atheist – Patheos

An 80-year-old retired professor has given the University of Texas a $1 million endowment to study Secular Americans.

Brian Bolton gave the money to UT a school he has no formal connection to in the hopes that a professor would study the ever-growing segment of non-religious people in the country.

Bolton has a long history of promoting atheism on his own. This site even published one of his articles in 2016.

UT will be the first public university to have an endowed chair for secular studies, said professor Phil Zuckerman, an assistant dean at Pitzer College in Claremont, Calif., where the first secular studies program in the nation was created.

For me, this is a dream come true, Zuckerman said. As more and more people are leaving religion, we need to understand who they are and how they live their lives and why they are doing it.

In addition to Zuckerman, who helped create that secular studies program, theres also an endowed Chair for the Study of Atheism, Humanism and Secular Ethics at the University of Miami. However, even the professor in that role teaches other philosophy courses. This endowment will allow for someone to focus on Secular Americans 100% of the time.

Its not a bad use of the money at all considering all the research that has yet to be done on our community. Theres value in formally studying our ethics, political leanings, desires, motivations, and problems. While researchers may focus on us for a paper or two, theres not always an incentive to do that long-term. This money allows someone to do just that without worrying about job security, at least for several years.

(Image via Shutterstock. Thanks to Charlie for the link)

View post:

Atheist Gives U. of Texas $1 Million Endowment to Study Non-Religious Americans - Friendly Atheist - Patheos

Yes, There Are Atheists Who Still Fear Hell – Patheos

I received this email over the weekend, which I will keep anonymous,

Even though I no longer believe I still find myself AFRAID of Hell. It was beaten into me for so many years it is like a fear that I am finding difficult to shake.

So my question is what advice could you give me to get over this fear. Maybe you could do a blog on this topic. It is so difficult to get over this very real fear. I want to enjoy my atheism as you and many others do but this fear of hell is truly Hell.

I am shocked and devastated to find out that this is true. I suppose I always just assumed that when you free yourself of religion, your lack of belief protects you from this fear. The fact that its been beaten so thoroughly into you that even disbelief in the deity that sends you to Hellcant stop you from fearing it, is really sad. I have to say, I feel for those of you who struggle with this, and I am so sorry you have to.

Ive been an atheist my entire life. I dont know what its like to fear Hell. I cant fully comprehend such a fear, and as such, my advice for getting past it may be insufficient, but I will give it my best shot. Here are a few of my ideas:

1. Exposure. This tactic has long been used as a method to get over many fears and phobias. Obviously, you cant go to Hell and inspect the place, but what you can do is read about it. The more you read about it, the less clear your idea of Hell will become. Youll realize that many cultures throughout the ancient and modern worlds have had some awful place that sinners go to for eternal punishment. Just like the story of Jesus was told over and over again with different heroes for thousands of years before Christ, so has the story of Hell. Reading about it will prove to you that its nothing but a story. Here are some books about Hell that illuminate where this idea came from, all its different manifestations throughout history and the fact that not all of those stories can be true, so the likelihood is that none of them are:

These are a good start, but I would go further. Keep reading. The more you expose yourself to it, the more apparent it will become that there is no consistent view of Hell and its all just myth.

2.Remind yourself of how unjust the concept of Hell is.Here in Canada, we do not have the death penalty. In fact, the longest sentence a convict can get in the Canadian penal system is 25 years (considered life). God punishes people for eternity for lesser crimes than those committed by Canadians serving life in prison. Therefore, Canadians are more forgiving and merciful than God? Further, does it sound just to you that finite sins are met with infinite punishment?

3. Force yourself to see the gaping holes in the story of Hell. If a good, well-behaved, Christ-loving family has one member who is not saved does this family really experience bliss in Heaven knowing that their loved-one is burning for eternity? Ive heard many Christians explain away this problem by suggesting their memory is wiped of any loved ones in Hell as soon as they pass through the pearly gates. So, ultimately, in order for Heaven to be truly blissful for anyone who may have a loved one in Hell (or even just compassion for those burning for eternity), they basically have to play out a scene from Men in Black. Essentially, they have to be lobotomized to enjoy Heaven. What if a mothers precious only child is the one burning in Hell for being a nonbeliever while she is up in Heaven? A child who was her life, her everything, her very reason for breathing if her memory is wiped of that child, is she really herself anymore? That begs the question, whats the purpose of an afterlife if youre not yourself at all? See the hole. Ask the question. None of it makes any sense at all.

5. Focus on the things that you do know and can prove. For instance, you know you have this life to live. This is factual. An afterlife is something we have no evidence for, but we are all alive now. Reason with yourself that spending the one life you are sure of in fear of a lifeyou have no reason to believe exists, is a waste of this life. Youre wasting what youre absolutely sure of, in fear of something for which there is zero evidence. Focus on the love of your family and friends, for which there is evidence. Spend time on your passions, for which there is evidence. Set goals and try to accomplish them, strive to build a better you in the here and now. Live your real life before you worry about anymythical one.

6. Read about reality and how this Universe ticks. Expose yourself to awe-inspiring questions, like the ones we all had after watching Cosmos or reading TheDemon-Haunted World Could there be life out there somewhere? What would that life look like? Will we ever be able to travel between galaxies and set foot on new planets? If youre like me, these questions lead to more questions, and leave me with a sense of awe and wonder so huge I can barely contain it.Try thinking about Hell after youve thoroughly considered the sheer vastness of our universe. Suddenly, it may seem sort of silly.

7. Focus on the idea of a loving god. If you spend your life being kind, fulfilling your obligations, caring for those in your life and just being an all-around good person, would a loving god really burn you in hell for eternity just because youve used the brain he gave you to think critically? No. Thats not a loving god at all. So, even though you dont believe in him anymore, there is obviously still a part of you that wonders, what if its true? If it is true, and youve been kind and good, and he is indeed a loving god, then you have all your bases covered.

8. Keep reading the case against Hell. Here are some fantastic resources:

Ultimately, this is going to take time and I imagine it is hard to rationalize. Be patient with yourself and dont give up. Supplement these points by reading some Joseph Campbell and watching his 6 part interview with Bill Moyers, The Power of Myth. Eventually, I would be willing to bet, you will be able to put your fear behind you and finally move on to that stage of being able to enjoy your new-found freedom.

Im writing a book addressing the many reasons believers distrust atheists. Im around 40,000 words in! If you want to help me get it done, you can support me by donatinghereor becoming a patronhere.

Image: Creative Commons/Pixabay

Go here to see the original:

Yes, There Are Atheists Who Still Fear Hell - Patheos

Podcast Ep. 308: Mitt Romney Did the Right Thing for the Wrong Reason – Patheos

In our latest podcast, Jessica and I discussed the past week in politics and atheism.

We talked about:

Donald Trump, without a hint of irony, said he doesnt like when religion is used to justify anything improper. (2:45)

FOX News is furious that Mitt Romney cited his religion when voting to impeach Trump. (6:20)

Conservatives are still furious over the Super Bowl halftime show. (9:50)

A pastor said God is the only reason he hasnt murdered one of his critics. (22:28)

No UK venue wants to make money off of Christian bigot Franklin Graham. (25:10)

A Christian activist said he would vote for Trump over Jesus. (27:38)

The ACLU held an LGBTQ Day at the Indiana Statehouse. (31:22)

A 4-year-old is dead because his anti-vaxxer mom didnt give him Tamiflu. (37:30)

This new Starbucks ad about a trans teen is fantastic. (43:04)

Planned Parenthood is expanding in Kentucky. (46:00)

Wed love to hear your thoughts on the podcast. If you have any suggestions for people we should chat with, please leave them in the comments, too.

You can subscribe to the podcast on iTunes or Google Play, stream all the episodes on SoundCloud or Stitcher, or just listen to the whole thing below. Our RSS feed is here. And if you like what youre hearing, please consider supporting this site on Patreon and leaving us a positive rating!

(Image via Shutterstock)

The rest is here:

Podcast Ep. 308: Mitt Romney Did the Right Thing for the Wrong Reason - Patheos

Study Shows How Soap Molecules Alter the Protein Structure – AZoM

Written by AZoMFeb 10 2020

During the production of cosmetics and detergents, it is important to control the structure of proteins. But so far, there has been no clear understanding of how both proteins and soap molecules work together to alter the structure of proteins.

Scientists at Aarhus University have successfully produced a comprehensive picture of how soap molecules are able to refold and unfold the proteins on the millisecond timescale.

Figuring out the interactions between soap molecules (surfactants) and proteins has traditionally been significant for the industry, specifically within cosmetics and detergents.

It is known that sodium dodecyl sulfate (SDS)an anionic surfactantunfolds globular proteins, whereas octaethylene glycol monododecyl ether (C12E8)a non-ionic surfactantdoes the reverse, that is, it helps proteins to refold into a shape.

If washing powders had to work efficiently, then it should be ensured that the surfactants do not alter the structure of proteins or enzymes. This is because any changes in the structure of the enzymes destroy their potential to remove dirt or break down stains.

A majority of the washing powders contain a combination of surfactants that enable the enzymes to stay active. Moreover, certain biotechnologies tend to manipulate the surfactants along with proteins.

Generally, membrane proteins are present in the cell membrane. To extract these membrane proteins from this setting for various analyses, they need to be solubilized by the surfactant. This surfactant should be sufficiently gentle and only enclose the membrane-inserted portion of the proteins, so that their structure is not disturbed.

On the other hand, when the molecular weight of proteins is being characterized in the laboratory, one typical method is to unfold these proteins by SDS, which happens to be the aggressive negatively charged surfactant, and track how these proteins move in a polymer gel within an electric field. But this method works only when the surfactant fully unfolds the proteins and damages their structure.

A debate is still going on about which kind of interactions between the surfactant and the protein is most significant. Is it the electrostatic interactions that occur between the protein and the surfactant charges, or is it only the characteristics of the interface of the aggregates (micelles) that the surfactants form in water, which account for protein unfolding?

Despite a thorough analysis of the unfolding processes at the protein level, a clear picture of the communication between surfactant and protein is not available in these processes. This lack of understanding has been addressed in the present work by utilizing the globular protein -lactoglobulin, or bLG, as a model protein.

A better understanding of the refolding and unfolding of proteins was achieved by plotting the numerous steps of protein-surfactant interactions as a function of time.

At first, bLGthe model proteinwas combined with the anionic surfactant SDS and, at the same time, the time evolution of the development of complexes between surfactant and protein molecules was tracked on the time scale ranging from milliseconds to minutes.

This method allowed the scientists to establish the structure of the emerging complexes. The team then plotted the time course of the refolding process when C12E8, a non-charged surfactant, was introduced to a sample comprising complexes of protein and SDS.

To visualize the way the protein reassembles during the course of the refolding and unfolding process caused by surfactants, complementary spectroscopic methods like tryptophan fluorescence and Circular Dichroism were employed together with time-resolved Small-angle X-ray scattering, or SAXS.

While variations in the bLG structure were tracked by both tryptophan fluorescence and Circular Dichroism, variations in the total shape of the complexes of protein and surfactant were monitored by synchrotron SAXS. Earlier, such kinds of combined techniques have never been used to analyze these processes.

Protein unfolding by SDS was a uniform process, in which all the molecules of proteins follow the same path of unfolding. The SDS complexes, or micelles, directly attack the protein molecules and then slowly unfold the protein so that it creates a shell over the SDS micelle. The refolding process begins when C12E8 micelles form mixed SDS-C12E8 micelles by sucking out the SDS from the protein-SDS complex.

But the actual refolding process appears to follow a number of paths, as numerous structures were observed to form simultaneously, such as mixed micelles of C12E8 and SDS, protein-surfactant complexes (perhaps comprising both C12E8 and SDS), properly folded proteins, and naked proteins that unfolded just like long polymeric chains.

The experiment made it possible to track the inter-conversion between these species, so that the type of processes that are fast and the ones that are slow can be determined.

The folded protein is likely to form from the naked unfolded proteins (quickly) and also from the complexes of protein and surfactants (more gradually). Hence, the most optimal way where surfactants can assist in the protein folding process is to essentially get out of the way and allow the protein to trace its own way back to the folded state.

The outcomes have given a better understanding of the structural variations that take place at the proteinsurfactant level. The results also demonstrated that refolding and unfolding of proteins mediated by surfactants are intricate processes of rearrangements that take place on time scales from less than milliseconds to minutes and also involve a close association between proteins and surfactant complexes.

The Independent Research Fund Denmark funded the study. The study was performed by scientists from Interdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, and Department of Molecular Biology and Genetics at Aarhus University, in association with scientists from ESRFThe European Synchrotron in Grenoble (France).

Professor Jan Skov Pedersen (iNANO and Department of Chemistry, Aarhus University) and Professor Daniel E. Otzen (iNANO and Department of Molecular Biology and Genetics, Aarhus University) were in charge of the research group.

Source:https://international.au.dk/

Go here to see the original:
Study Shows How Soap Molecules Alter the Protein Structure - AZoM

The keto diet: Its highs and lows plus 5 recipes – The Gazette

By Daniel Neman, St. Louis Post-Dispatch

My friends Mike and Robin have been on the keto diet for a couple of years. They lost a ton of weight, and they look fit and trim better than Ive ever seen them, and Ive known them more than 30 years.

Their results are not unusual. The keto diet often leads to rapid weight loss.

The trick lies in keeping it off. Mike and Robin have done it well, but a lot of people cant. And therein lies a problem, according to Jennifer McDaniel, a registered dietitian and the owner of McDaniel Nutrition Therapy in St. Louis.

While you might gain benefits in the short term just like any other restrictive diet, most people like, 90% of the people have trouble staying on it. When they lose the weight and they cant maintain the weight that they attained, thats just another failed diet, she said.

The keto diet is a high-fat, low-carbohydrates diet its like the Atkins diet on steroids, McDaniel said. People on the diet strive to consume 70% to 80% of their calories through fats, as little as 5% through carbohydrates and the rest through protein.

This helps us lose weight because it forces our bodies to burn fat for energy instead of its preferred fuel, carbohydrates.

McDaniel recommends that her clients not go on the keto diet. The diet changes the microbiome in their bodies (the bacteria, fungi and more that live inside us). It is difficult for people on the diet to consume enough fiber, which can lead to constipation and other gastrointestinal nastiness. And because carbohydrates hold onto water, people on the diet are often dehydrated, she said.

And yet, as Mike and Robin and thousands of others can attest, it works. So I decided to try a few recipes to see how they tasted.

ARTICLE CONTINUES BELOW ADVERTISEMENT

The rules of the keto diet are highly restrictive, which can make cooking difficult. You need to avoid fruit, sugars, grains, beans and legumes, rice, potatoes, candy and juice.

Ingredients to be encouraged include meat, fatty fish, eggs, butter and cream, cheese, nuts and seeds, certain oils (olive, avocado, coconut) and low-carb vegetables most green vegetables, tomatoes, onions, peppers and the like.

Its a lot to take in, so I began with a simple and entirely wonderful dish of Citrus-Marinated Olives. These are a marvelous treat, combining the heady earthiness of olives with bright notes of orange and lemon. Though the flavors are disparate, they work surprisingly well together.

Best of all, you make them in mere minutes.

Another winner was Keto Egg Cups, a dish that concisely presents everything that is good about keto cooking: Little cups made from prosciutto hold eggs mixed with cream, spinach, roasted red peppers and mozzarella and Parmesan cheeses.

Its a delightful conglomeration of high-fat goodies that come together into a hand-held snack. And its just as fun at room temperature as it is warm.

Two entrees came next. First, I took a recipe for Instant-Pot Keto Mediterranean Chicken and made it a recipe for Keto Mediterranean Chicken Without an Instant Pot. It only took about five minutes longer than the Instant-Pot version, and it was deeply satisfying.

Ill admit, though, that I could not commit to full keto cooking with this one. As written, the recipe calls for searing six chicken thighs and then cooking the dish in the resulting fat.

My six thighs rendered out a half cup of fat. I just couldnt do it. I couldnt cook with and I certainly couldnt eat that much fat. I know the keto diet requires what seems like a shocking amount of fat to work, but I just couldnt see it. I poured out half of the fat, and the dish still felt greasy to me.

ARTICLE CONTINUES BELOW ADVERTISEMENT

Greasy, but delicious. Meaty chicken thighs are paired with olives, capers, oregano and a cutting splash of vinegar. Its presented with a fresh-tasting yogurt sauce, making an impressive presentation. Id happily eat it anytime, especially if I poured out all but one tablespoon of that fat.

The other entree, Keto Breaded Chicken Cutlets, isnt bad but Id only make it again if I were on the keto diet. The chicken is dredged through almond flour before frying, which gives it a duller flavor than wheat flour.

With wheat flour, the same recipe would be excellent, if familiar. If youre on the keto diet, almond flour is definitely the way to go. Just be sure to use a lot of salt.

The last dish I made was a dessert called Black and White Keto Fat Bombs. Seriously, thats the name, and seriously, thats what they are. They are chocolate-and-vanilla candies that are made with coconut oil and almonds, plus low-carb, powdered sweetener, sugar-free vanilla extract and unsweetened cocoa powder.

How did they taste? Not bad, actually, or at least not too bad. But the texture was so oily and off-putting that most taste testers threw away their samples. One said it was like eating butter.

If youre on the keto diet and youre looking for an extra infusion of fat, then Id say to go ahead and make it. Otherwise, this is one to avoid.

My friend Robin swears by the keto diet and says she is passionate about it. Her health indicators are all great, and she says she has higher energy and alertness. And though the diet is restrictive, she likes what she can eat: cheese, olive oil, butter, nuts and dark chocolate.

The biggest thing she misses is fruit, but she does not miss the 40 pounds she lost.

Then again, I have another friend, Roger, who lost 65 pounds. He just eats more healthfully and mindfully, and walks every day. That sounds easier.

BLACK AND WHITE KETO FAT BOMBS

Yield: 15 servings

2 cups slivered almonds

1 cup coconut oil

1 to 2 tablespoons of your favorite low-carb powdered sweetener

1 teaspoon orange zest

2 teaspoons vanilla extract (sugar-free if on keto diet)

Small pinch salt

2 tablespoons unsweetened cocoa powder

Line a mini-muffin tin with mini liners.

ARTICLE CONTINUES BELOW ADVERTISEMENT

Pulse and then process the almonds, oil, sweetener, vanilla, zest and salt until smooth except for small chunks of almond (like chunky peanut butter). Remove half to a small bowl and stir in the cocoa powder.

Fill half of one liner with the vanilla mixture and then quickly fill the other half with the chocolate mixture (it should remind you of a black-and-white cookie). Repeat with the remaining vanilla and chocolate mixtures. Tap the tin on the counter a few times.

Freeze until solid, about 30 minutes. You can remove the liners if youd like. Refrigerate in an airtight container for up to 5 days.

Per serving: 243 calories; 24 g fat; 13 g saturated fat; no cholesterol; 4 g protein; 5 g carbohydrate; 1 g sugar; 3 g fiber; 155 mg sodium; 53 mg calcium

Source: Food Network

KETO MEDITERRANEAN CHICKEN

Yield: 4 servings

1 tablespoon olive oil

8 bone-in, skin-on chicken thighs

Salt and pepper

3 garlic cloves, thinly sliced

1 cup pitted kalamata olives

2 tablespoons capers

2 tablespoons white wine vinegar

1 1/2 teaspoons dried oregano

1 cup whole-milk Greek yogurt

1/4 cup fresh flat-leaf parsley, roughly chopped

2 tablespoons fresh mint leaves, roughly chopped

1 teaspoon lemon zest

1 tablespoon lemon juice

Heat oil in a large pot or Dutch oven over medium heat. Liberally sprinkle chicken with salt and pepper and cook half of the pieces, skin-side down, until the skin is deeply browned, 6 to 8 minutes. Flip and cook until the other side is deeply browned, 4 to 6 minutes. Transfer to a plate and repeat with remaining pieces of chicken.

Pour out all but 1 tablespoon of the fat (if on the keto diet, keep all the fat in the pot). Return pot to heat and add garlic; cook until golden brown, about 1 minute. Add the olives, capers, vinegar, oregano and 1/2 cup water; stir to combine and to scrape up any browned bits at the bottom of the pot. Return chicken pieces to pot and stir to mix.

Cover and cook at a simmer until chicken is done, about 30 minutes. Remove the chicken and boil the sauce to reduce it by half.

Meanwhile, mix the yogurt, parsley, mint, lemon zest and lemon juice, plus a large pinch of salt and pepper. Stir to combine. Taste and season with more salt and pepper, if needed.

Serve the chicken with its sauce, and the yogurt sauce on the side.

ARTICLE CONTINUES BELOW ADVERTISEMENT

Per serving (nutrition calculated using all the fat from step 2): 627 calories; 48 g fat; 12 g saturated fat; 285 mg cholesterol; 42 g protein; 5 g carbohydrate; 1 g sugar; 2 g fiber; 1,146 mg sodium; 91 mg calcium

Source: Adapted from a recipe by the Food Network

KETO EGG CUPS

Yield: 3 servings

1 tablespoon butter, see note

6 large, thin slices of prosciutto

1/3 cup shredded mozzarella cheese

1/4 cup grated Parmesan

1/4 cup packed baby spinach leaves, chopped

1/4 cup roasted red peppers, chopped

6 large eggs

1/4 cup heavy cream

Salt and pepper

Note: To make this recipe even more keto-friendly, instead of greasing the muffin tin with 1 tablespoon of butter, melt 2 tablespoons and brush the tin with it. It will pool in the bottom of each cup, but that is OK.

Position an oven rack in the center of the oven and preheat to 400 degrees.

Grease the cups of a muffin tin with the 1 tablespoon of butter (or brush with 2 tablespoons of melted butter). Line each cup with a slice of prosciutto, folding and overlapping so that the entire surface of the cup is covered and no metal is peeking through. Divide the mozzarella evenly among the cups. Repeat with the Parmesan, spinach and roasted red peppers.

Whisk the eggs and cream in a large measuring cup or small pitcher; add some salt and a few grinds of pepper. Pour the egg mixture in each cup, making sure not to overfill.

Bake until the eggs are set and wobble only slightly, 10 to 12 minutes (the eggs will continue to cook after they come out). Let cool 5 minutes, then use a thin knife or offset spatula, if necessary, to loosen the prosciutto from the edges of each cup. Transfer to a plate for serving.

Per serving: 321 calories; 22 g fat; 10 g saturated fat; 426 mg cholesterol; 28 g protein; 4g carbohydrate; 1 g sugar; 1 g fiber; 1,779 mg sodium; 272 mg calcium

Source: Food Network

CITRUS-MARINATED OLIVES

Yield: 4 to 6 servings

1/4 cup olive oil

1/4 teaspoon crushed red pepper flakes

2 sprigs fresh thyme

1 garlic clove, thinly sliced

1 strip lemon zest, removed with a vegetable peeler

1 strip orange zest, removed with a vegetable peeler

Salt and pepper

1 cup Castelvetrano olives

1 tablespoon lemon juice

1 tablespoon orange juice

Heat the olive oil in a small saucepan over medium heat. Add the red pepper flakes, thyme, garlic, lemon zest, orange zest, salt and pepper to taste and cook, stirring occasionally, until garlic is pale golden, about 2 minutes. Stir in olives and cook until just warm, 2 minutes. Remove from heat and stir in lemon juice and orange juice. Serve warm or at room temperature.

Per serving (based on 4): 167 calories; 18 g fat; 3 g saturated fat; no cholesterol; 1 g protein; 4 g carbohydrate; 1 g sugar; 2 g fiber; 829 mg sodium; 39 mg calcium

Read the original post:
The keto diet: Its highs and lows plus 5 recipes - The Gazette